Flibanserin, a drug produced by Sprout Pharmaceuticals, recently passed an FDA advisory committee meeting.
The drug, marketed as Addyi, has been criticised as having marginal benefits.
Unlike
Viagra, which affects blood flow to the genitals, Addyi is designed to
help women regain their sex drive by boosting levels of brain chemicals.
Sprout said
trials had shown an increase "in the number of satisfying sexual
events", although experts suggest the test results were modest.
'An unmet need'
Versions of the pill have been submitted for approval in the past but never passed.
It was rejected by the FDA twice for lack of effectiveness and side effects like nausea, dizziness and fainting.
But an FDA advisory meeting on 4 June concluded by 18 votes to six that it should be approved.
The
FDA said strict measures would be put in place to ensure patients were
aware of the risks, including a warning not to drink alcohol with the
drug.
It will be made available through certified health care professionals and pharmacies from October.
No comments:
Post a Comment